Used in pharmaceutical research as a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), this compound plays a key role in the development of treatments for type 2 diabetes. By inhibiting DPP-4, it enhances the activity of incretin hormones such as GLP-1, which stimulate insulin release in a glucose-dependent manner, helping to lower blood glucose levels without causing hypoglycemia. Its structure enables high binding affinity and prolonged action, making it a candidate for once-daily oral therapy. It has shown favorable pharmacokinetic and safety profiles in preclinical studies, supporting its use in advanced drug development for metabolic disorders.